Eikon Therapeutics, Inc.
EIKN
$10.73
$0.020.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | -6.29% | 16.86% | 27.43% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 9.45% | 22.35% | 22.41% | ||
| Operating Income | -9.45% | -22.35% | -22.41% | ||
| Income Before Tax | 15.97% | -21.56% | -22.69% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | 15.97% | -21.56% | -22.69% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | 15.97% | -21.56% | -22.69% | ||
| EBIT | -9.45% | -22.35% | -22.41% | ||
| EBITDA | -8.81% | -21.49% | -21.20% | ||
| EPS Basic | 95.58% | 91.21% | -8.37% | ||
| Normalized Basic EPS | 94.25% | 90.01% | -8.10% | ||
| EPS Diluted | 95.58% | 91.21% | -8.37% | ||
| Normalized Diluted EPS | 94.25% | 90.01% | -8.10% | ||
| Average Basic Shares Outstanding | 1,800.76% | 1,116.23% | 13.21% | ||
| Average Diluted Shares Outstanding | 1,800.76% | 1,116.23% | 13.21% | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||